🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Design and main results: 🚩MDT vs ENRT, both arms 6mo of ADT 🚩Higher GU2+ tox in ENRT arm, but mainly due to more prostate bed RT in this arm 🚩Omitting PB RT results in higher rate of local failures 🚩Locoregional control superior with ENRT: 90% control @ 3yr. 🏴MFS not mature

💫🌟Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis🌟💫 Soumyajit Roy (Soum), Daniel E Spratt, Yilun Sun, Amar Kishan, Dr. Andrew Loblaw, Fred Saad, Christopher Wallis (he/him/his), Scott C. Morgan OncoAlert 🔹 Comparative Study: Meta-analysis of

SOLAR Phase 2 trial: multimodal therapy without long-term castration ➡️de novo oligometastatic PCa ➡️RP or RT to the primary + MDT (SBRT) + Intensified systemic therapy for 6 months (ADT+Apa+Abi) ➡️Primary endpoint: percentage of patients with testosterone ≥150 and undetectable

1/6 New Article Alert Hot in @BMJ_Oncology, our prospective study investigates the 🤔 #Bladdercancer treatment dilemma: 🔪 Radical cystectomy vs 🎯 Bladder preservation have Similar survival, but what about QOL? Tata Memorial Hospital TMC Radiation Oncology Sheetal R Kashid

So grateful to share my interview for UroToday.com about our RADIOSA trial! Watch the video to find out the preliminary results! Zach Klaassen urotoday.com/video-lectures…

Interesting efficacy signal for bladder preservation (TMT) + nivolumab. Increased #bladdercancer free survival & OS va TMT No new safety issue. Additional data expected from GETUG Bladder Sparing study. Larger trials needed. #ESMO2024

🍺🍻🇩🇪 Oktoberfest lectures #radonc - Thomas Zilli 🇨🇭and Joost Verhoeff 🇳🇱 speak about single fraction #radiotherapy. I learned that beer was brewed a long time ago! Oh - and that RADIOSURGERY is being tested in Ventricular arrhythmia 🫀and #prostatecancer.

A #prostatecancer masterclass by Bram De Laere on the first ProBio results. My take home message: Physicians choosing the treatment based on their “experience” is not the best option. First randomized results in mCRPC of ARPI vs Tax! Paper here tinyurl.com/52nhuudd

RAIDER trial out in European Urology europeanurology.com/article/S0302-… Congrats to Robert Huddart💙 Prof Emma Hall Prof Ananya💙 @achoud72.bsky.social on this large trial of bladder preservation with innovative exploration of adaptive therapy. Extremely low rates of grade 3 toxicity and salvage cystectomy

Team effort 🇬🇧👏🏽 Many interesting observations Robert Huddart💙 Follow us on Bluesky @ICR-CTSU 💙alison birtle ➡️ Low toxicity ➡️ Outcomes 🟰 modern surgery ➡️ Low pelvic N recurrence with bladder only RT ➡️ DART & PoD non-significantly better ➡️ We don't need high tech or £££ for bladder preservation

Interesting analysis of CHHiP trial, which answers our “overall Gleason” (UK) vs “worst Gleason” (US) debate. Seems it doesn’t matter pubmed.ncbi.nlm.nih.gov/37463104/ It does suggest specialist path review is more prognostic than initial path report =important Anna Wilkins Follow us on Bluesky @ICR-CTSU

I enjoyed his collaboration led by Nora Sundahl & Shankar Siva with many friends and colleagues in the field, published European Urology cc: Dana-Farber Lank Center for Genitourinary Oncology Dana-Farber Lank Center for Genitourinary Oncology Rana McKay, MD, FASCO Laurence Albiges Chad Tang, MD sciencedirect.com/science/articl…

🏅Secondary result: We found a linear relationship between ctDNA 🩸 levels and outcome: 📉 Every 10% increase in ctDNA fraction led to a 9% decrease in the observed survival time. 💡 The more ctDNA in🩸, the worse the outcome! #PrecisionMedicine [5/8]

Wee Loon Ong leads pub in European Urology Oncology for #PATRIOT (#SBRT weekly vs every other day treatment for favourable risk #prostatecancer ) No stat diff in bioc fail (mFU of 91mo) Planning to combine with Thomas Zilli #NOVALIS study (same design) free link👉tinyurl.com/yyhd69c2

HRQOL in MIBC: RC vs bladder preservation. New Dutch cohort data show both approaches yield high HRQOL at 2 years, but RC had better pain and body image outcomes. Sexual symptoms worse after RC. Tailored decision-making is key. #BladderCancer #ESTRO2025 #RadOnc

Paul Sargos presenting very reassuring early toxicity results from GETUG adjuvant radiotherapy trial after cystectomy for #bladdercancer #ESTRO25

🔬 10-year HYPO-RT-PC trial update: UHF 📆2.5 weeks 7# = CF 📆8 weeks 39# ✅ Same survival & toxicity ➡️ UHF may be more efficient! #ESTRO25 #ProstateCancer

🚨10y results of HYPO RT PC at #ESTRO25 Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT 1. Non inferior for FFS (even better?) 2. Similar bPFS, DMFS, ADT use, OS 3. Similar GU/GI tox (except transient flare at 1y for UHF)

“‘SBRT for localised prostate cancer is ready for prime time!’ At #ESTRO25, Nicholas van As confirmed SBRT as a strong, precise, and low-toxicity option for prostate cancer. More data coming! #SBRT #ProstateCancer #Radiotherapy #ESTRO2025”

🔥⚡️🚀Adjuvant RT after cystectomy in high-risk bladder cancer: •25–30% LRR despite chemo •Safe (<5% G3–4 toxicity, 3 RCTs) •RT ↓ LRR = worthy goal Presented by Dr. Vedang Murthy Murthy at #ESTRO2025 #BladderCancer #Radiotherapy #OncoTwitter